Shots:
- Mabwell has entered a licensing and commercialization agreement with a Malaysian partner for its denosumab biosimilars, Mailishu (biosimilar, Prolia) and Maiweijian (biosimilar, Xgeva)
- As per the deal, the partner will handle registration and commercialization in Malaysia
- While Mabwell will oversee the development, manufacturing, and supply of the products
Ref: Mabwell | Image: Mabwell | Press Release
Related News: Mabwell Initiates P-III Trial for 9MW2821 in TNBC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
